22 hrs ago
Press release distribution, EDGAR filing, XBRL, regulatory filings
The notes ... )--Fitch Ratings has upgraded four and affirmed nine classes of COMM Mortgage Trust 2004-LNB2, commercial mortgage pass-through certificates.
Trending on the Topix Network
Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period and year ended December 31, 2013.
Wed Mar 05, 2014
Spectrum Pharmaceuticals (SPPI) to Release Quarterly Earnings on Thursday
Spectrum Pharmaceuticals is scheduled to announce its Q313 earnings results on Thursday, March 6th.
Thu Feb 27, 2014
Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast
For interested individuals unable to join the call, a replay will be available from March 6, 2014 @ 7:30 p.m. ET/4:30 p.m. PT through March 19, 2014 until 11:59 p.m. ET/8:59 p.m. PT.
Fri Feb 21, 2014
FDA Gives Topotarget Acceptance To File For Beleodaq
Topotarget announced in a press release that the Food and Drug Administration has given acceptance to file for Beleodaq.
Thu Feb 13, 2014
The Zacks Analyst Blog Highlights:Gilead, Cytokinetics, Puma, Biogen and Spectrum Pharmaceuticals
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Wed Feb 12, 2014
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for ...
"The Priority Review designation for the Beleodaq NDA acknowledges the potential significant improvement in its safety or effectiveness for the treatment for patients with the serious condition of R/R PTCLs when compared to standard applications.
Tue Feb 11, 2014
Spectrum Pharmaceuticals Partnering 2005-2013 - new company profile report published
The Partnering Agreements with Spectrum Pharmaceuticals 2005-2013 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
Mon Feb 10, 2014
The Motley Fool
Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?
Spectrum's fall during a time when the entire biotech sector has been soaring seems odd.
Thu Feb 06, 2014
FDA grants acceptance to file and Priority Review for Beleodaq (belinostat) NDA in PTCL
Topotarget A/S announces that the FDA has granted acceptance to file and Priority Review for the BeleodaqTM NDA for the treatment of relapsed or refractory PTCL.
Spectrum Pharmaceuticals Inc Files (8-K) Disclosing Triggering Events ...
SPECTRUM PHARMACEUTICALS INC FILES Disclosing Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits Item 2.04.
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA...
'The FDA's acceptance of this NDA submission is another important milestone in our strategy to bring Beleodaq to market, and one step closer to the possible availability of more treatment options to address the unmet medical need for patients with R/R PTCL,' said .